痴呆
认知功能衰退
神经心理学
认知
记忆诊所
口语流利性测试
语言学习
波士顿命名测验
心情
人口
医学
神经心理学测验
认知测验
认知储备
听力学
内科学
心理学
临床心理学
精神科
疾病
环境卫生
作者
Salvatore Mazzeo,Michael Lassi,Sonia Padiglioni,Valentina Moschini,Alberto Arturo Vergani,Maenia Scarpino,Giulia Giacomucci,Rachele Burali,Carmen Morinelli,Carlo Fabbiani,Juri Balestrini,Giulia Galdo,Silvia Bagnoli,Filippo Emiliani,Assunta Ingannato,Benedetta Nacmias,Sandro Sorbi,Antonello Grippo,Alberto Mazzoni,Valentina Bessi
摘要
Abstract Background Subjective cognitive decline (SCD) represents a target population to be screened for dementia. Previous studies identified demographic, cognitive and generic features associated with higher risk of progression to mild cognitive impairment (MCI) and Alzheimer’s disease (AD). We aim to test the accuracy of a machine learning model, trained on features derived from non‐invasive and easily accessible techniques, in predicting conversion from SCD to MCI and AD. Method We included 150 SCD patients who underwent neuropsychological examination, assessment of cognitive complaint, mood disorders and cognitive reserve, APOE genotyping at baseline. All the patients underwent clinical‐neuropsychological follow‐up every 12‐24 months for a mean time of 12 years. Result During follow‐up, 63 patients were classified as progressive SCD (p‐SCD, 42.0%[95% C.I. = 34.1:49.9], including 41 MCI (27.3% [95%C.I. = 20.2:34.5]) and 22 AD (14.7% [95%C.I. = 9.0:20.3]). 87 patients were classified as non‐progressive SCD (np‐SCD, 58.0% [95%C.I. = 50.1:65.9]). We split the whole sample into a training (80%) and a test group (20%). A gradient boosted trees algorithm was trained on 15 selected features including: age, APOE, education, test assessing for global cognition, immediate and delayed verbal, ecological memory and working memory, language, visuospatial abilities, phonemic fluency and cognitive reserve (Fig.1). This model showed a good accuracy (0.83, AUC = 0.78) in distinguishing p‐SCD and np‐SCD in the test group (Fig.2 and Fig.3). Conclusion Our machine learning models might represent a reliable, cost‐effective and globally scalable tool for a first step screening of SCD patients before confirmation of AD pathology via more invasive and expensive tests.
科研通智能强力驱动
Strongly Powered by AbleSci AI